Sarepta Therapeutics (SRPT) Non Operating Income (2010 - 2026)

Sarepta Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$15.3 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 81.64% year-over-year to -$15.3 million in Q1 2026; TTM through Mar 2026 was $65.4 million, a 239.26% increase from a year earlier, with the FY2025 full-year figure at -$2.4 million, down 105.72% from the prior year.
• Non Operating Income declined to -$15.3 million in Q1 2026 per SRPT's latest filing, from $133.3 million in the prior quarter.
• Across five years, Non Operating Income topped out at $133.3 million in Q4 2025 and bottomed at -$374.6 million in Q1 2023.
• The 5-year median for Non Operating Income is -$12.3 million (2023), against an average of -$29.8 million.
• Across the five-year window, Non Operating Income sank 2069.83% in 2023 and surged 1224.66% in 2025, its largest moves.
• Year by year, Non Operating Income stood at -$119.9 million in 2022, then surged by 113.13% to $15.7 million in 2023, then tumbled by 36.1% to $10.1 million in 2024, then jumped by 1224.66% to $133.3 million in 2025, then sank by 111.45% to -$15.3 million in 2026.
• Per Business Quant, the three latest SRPT Non Operating Income figures stand at -$15.3 million (Q1 2026), $133.3 million (Q4 2025), and -$90.7 million (Q3 2025).